U.S. markets closed

Recursion Pharmaceuticals, Inc. (RXRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.26+0.02 (+0.22%)
At close: 01:00PM EST
9.39 +0.13 (+1.40%)
After hours: 03:29PM EST

Recursion Pharmaceuticals, Inc.

41 South Rio Grande Street
Salt Lake City, UT 84101
United States
385 269 0203

Full Time Employees400

Key Executives

NameTitlePayExercisedYear Born
Dr. Christopher C. Gibson Ph.D.Co-Founder, CEO & Director673.59kN/A1983
Ms. Tina Marriott LarsonCOO & Pres595.95kN/A1975
Dr. Blake C. Borgeson Ph.D.Co-Founder & Director30kN/A1982
Dr. Michael Secora Ph.D.Chief Financial Officer510.34kN/A1983
Dr. Shafique Virani M.D.Interim Chief Medical Officer & Chief Bus. Officer688.17kN/A1971
Kevin LeggatVP of Fin. & AccountingN/AN/AN/A
Mr. Benjamin Mabey M.S.Chief Technology OfficerN/AN/A1983
Mr. Jared AllenbachSr. Director of Investor RelationsN/AN/AN/A
Ms. Louisa Daniels J.D., M.B.A.Chief Legal Officer & Gen. CounselN/AN/A1958
Mr. Ryan KellyChief Communications OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Corporate Governance

Recursion Pharmaceuticals, Inc.’s ISS Governance QualityScore as of November 1, 2022 is 8. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 10; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.